Clinical trials: Hypereosinophilic Syndrome
Severe Asthma, Asthma in Children
Severe Eosinophilic Asthma Phenotypes During Childhood Have Various Origins
Study of the clinical evolution at 10 years of children from the SAMP cohort (severe asthma, eosinophilic or not, allergic or not) in order to understand the different possible evolutions of these phenotypes at different ages.
- Trial name
- SAMP 2 (NCT05762627)
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypereosinophilic Syndrome (HES)
MAP to Provide Access to Nilotinib, for Patients With HES
The purpose of this program is to allow access to nilotinib for eligible patients diagnosed with Hypereosinophilic syndrome (HES).
- Trial name
- NCT04498871
- Testing
- Nilotinib
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Hyperbilirubinemia
Study of Efficacy and Safety of the Plasmapheresis Method With Albumin Compensation Compared With the Plasmapheresis Method Without Albumin Compensation for Aging Biomarkers Correction in Men and Women Aged 40 to 55 Years Old
Reaching active aging makes it important to implement new methods affecting the biological age of a person. Biochemical parameters of a blood test are aging biomarkers that are ones of the most accessible for testing.
- Conditions
- Hypercholesterolemia, Hyperbilirubinemia, Hyper IgE Syndrome, Hyper Beta Lipoproteinemia
- Trial name
- NCT04897113
- Testing
- plasma exchange with albumin, plasma exchange without albumin
- Where
- 2 sites in Russia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Medical Research Center for Rehabilitation and Balneology
COPD Asthma, Eosinophilic Asthma
Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma.
- Trial name
- NCT05398133
- Where
- Poland
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Hypereosinophilic Syndrome
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with…
- Trial name
- NATRON (NCT04191304)
- Testing
- Benralizumab
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL)
Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as: 1.
- Conditions
- Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL), Myeloproliferative Disorders
- Trial name
- NCT00276926
- Testing
- STI571
- Where
- 14 sites in Italy
- Sponsor
- University of Bologna
Asthma; Eosinophilic
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Unicentric prospective real life study designed to analyse the efficacy of Dupilumab to reduce bronchial inflammation of asthma measured by inflammatory cell counts obtained in induced sputum and other related characteristics…
- Trial name
- DEBORA (NCT05787678)
- Testing
- Dupilumab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Asthma; Eosinophilic
Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
In this study, investigators want to evaluation of the impact of benralizumab (Fasenra®, Astra Zeneca) on different cell populations, including basophils and innate lymphoid cells, and several biomarkers, such as miRNAs, cadena α…
- Trial name
- BASEAS (NCT04742504)
- Testing
- BENRALIZUMAB
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Allergic Bronchopulmonary Aspergillosis, ABPA
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma
An open-label study will evaluate effects of Depemokimab in the treatment of severe eosinophilic asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma
- Trial name
- NCT07828327
- Testing
- Depemokimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Qianfoshan Hospital
Asthma
Small Particle Steroids in Refractory Asthma
The purpose of this study is to determine whether an inhaled steroid with a small particle size can be an additional treatment option in patients with refractory eosinophilic asthma.
- Trial name
- SPIRA (NCT01171365)
- Testing
- Ciclesonide
- Where
- 2 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Nottingham
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients…
- Trial name
- NCT01270464
- Testing
- Reslizumab
- Where
- 89 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.
- Trial name
- NCT01287039
- Testing
- Reslizumab
- Where
- 128 sites in United States, Australia and 15 more
- Volunteers
- 489 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bone and Joint Infection, Treated by Daptomycin
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
The choice of antimicrobial therapy to treat complex bone and joint infections (BJI) is challenging, requiring consideration of: (i) the problem of bone diffusion; (ii) the necessity of using antimicrobials active against…
- Trial name
- NCT03209934
- Volunteers
- 43 people
- Sponsor
- Hospices Civils de Lyon
Severe Eosinophilic Asthma, Psychological Distress
Severe Asthma, MepolizumaB and Affect: SAMBA Study
This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners.
- Conditions
- Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
- Trial name
- SAMBA (NCT04680611)
- Testing
- no study intervention. Patients receive standard clinical care
- Where
- 6 sites in United Kingdom
- Volunteers
- 120 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
- Trial name
- NCT01285323
- Testing
- Reslizumab
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 464 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Eosinophilic Asthma
A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma
This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma.
- Trial name
- BREADTH (NCT07323654)
- Testing
- KT-621
- Where
- 81 sites in United States, Argentina and 11 more
- Volunteers
- 264 people
- Sponsor
- Kymera Therapeutics, Inc.
Asthma
Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma
The aim of the project is to study the persistence of inflammation after addition of an interleukin-5 (IL-5) blocker in severe eosinophilic asthma as a study of untreated pathways in these patients.
- Trial name
- MAPLE (NCT03610685)
- Testing
- Prednisolone
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- NHS Greater Glasgow and Clyde
Eosinophilic Asthma
A Pragmatic Study to Investigate the Efficacy and Safety of Mepolizumab in Severe Uncontrolled Asthma in Brazil
The anti-interleukin-5 monoclonal antibody mepolizumab is approved as an add-on therapy in Europe, Canada, USA, and other countries, to standard of care for the treatment of patients with severe eosinophilic asthma.
- Trial name
- NCT04228588
- Testing
- Mepolizumab 100 MG [Nucala]
- Where
- Brazil
- Volunteers
- 18 people
- Sponsor
- University of Sao Paulo General Hospital
Severe Asthma
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the…
- Trial name
- PREPARE (NCT03931954)
- Where
- 18 sites in Argentina, Chile and 4 more
- Volunteers
- 794 people
- Sponsor
- AstraZeneca